Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06143631 · ClinicalTrials.gov registry record · Phase 4

Prescription of Letrozole for Uterine Myoma

A Phase 4 study of Leiomyoma and Fibroid Uterus, sponsored by University of California, San Francisco.

Recruiting
Registry status
Phase 4
Development phase
140
Enrollment target
5
Study locations

NCT06143631: Recruiting Phase 4 study of Leiomyoma and Fibroid Uterus, sponsored by University of California, San Francisco.

NCT06143631 is a Phase 4 study of Leiomyoma and Fibroid Uterus that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 140 participants, above the 88-participant average among 8 other Leiomyoma trials with a reported enrollment target (59% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06143631, a Phase 4 study of Leiomyoma and Fibroid Uterus, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
Phase 4
Development phase
140 participants
Enrollment target
5
Study locations

Study Summary

The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.

Primary Outcome

Change in Uterine Fibroid Symptoms Quality of Life (UFS-QOL) Symptom Severity Scale (SSS) score \[Range 8-40 with higher score indicating worse symptoms and worse outcomes\]

Interventions

  • OTHER Placebo
  • DRUG Letrozole 2.5mg

Study Locations (5)

California

  • University of California, Los Angeles - Los Angeles
  • University of California, San Francisco - San Francisco

Minnesota

  • Mayo Clinic - Rochester

Mississippi

  • University of Mississippi Medical Center - Jackson

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2024-07-24
Est. Completion 2027-04-30
Phase Phase 4

What NCT06143631 shows while recruiting

NCT06143631 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 88-participant average among 8 other Leiomyoma trials with a reported enrollment target (59% higher).

The record links to 4 conditions, with Leiomyoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06143631 lists 5 locations in 4 states (California, Minnesota, Mississippi).

Frequently Asked Questions

What is clinical trial NCT06143631 about?

NCT06143631 is a clinical study titled "Prescription of Letrozole for Uterine Myoma". The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.

What is the current status of trial NCT06143631?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2024-07-24. Estimated completion is 2027-04-30.

What conditions does trial NCT06143631 study?

This clinical trial studies the following conditions: Leiomyoma, Fibroid Uterus, Leiomyoma, Uterine, Fibroid.

What interventions are being tested in trial NCT06143631?

The interventions under investigation include: Placebo (OTHER), Letrozole 2.5mg (DRUG).

Who is sponsoring clinical trial NCT06143631?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06143631 being conducted?

This trial has 5 study locations across California, Minnesota, Mississippi, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Leiomyoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06143631's enrollment target sits among peer trials

140 3rd of 8 higher than 6 of 8 other Leiomyoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Leiomyoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02455193 · 140 participants · NA

    Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06143631, the US trial registry maintained by the National Library of Medicine. NCT06143631 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.